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Abstract
Patients with long-standing ulcerative colitis are at an increased risk for the development of intraepithelial neoplasia and
colitis-associated cancer, and guidelines recommend colonoscopy as an outcome parameter for biological therapies or to
assess therapeutic efﬁcacy. This video highlights the various endoscopic ﬁndings in different disease stages of ulcerative
colitis. The technique of advanced dysplasia detection in ulcerative colitis will be highlighted in another video of this
library. This article is part of an expert video encyclopedia.
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Video Related to this Article
Techniques
High-deﬁnition white-light endoscopy, virtual chromoendo-
scopy (i-scan), and methylene blue staining.
Materials
• Endoscope: 90i Colonoscope (Pentax, Hamburg, Germany).
• Video processor: EPK-i (Pentax, Hamburg, Germany).
• Solution: Methylene blue 0.1%.
Background and Endoscopic Procedure
Patients with long-standing ulcerative colitis are at increased
risk for the development of intraepithelial neoplasia and
colitis-associated cancer.1,2 In this context, the duration and
anatomic extent of the disease are well-established risk
factors for cancer development.3,4 In addition, national and
international guidelines recommend ileocolonoscopy as an
outcome parameter for biological therapies or to assess ther-
apeutic efﬁcacy.5
Standard white-light endoscopy is likely an insensitive test
for diagnosis of ulcerative colitis in the inactive or even mild
phase of the disease.6 Recent data indicate that advanced
endoscopic imaging techniques may improve the prediction of
disease activity in patients with inﬂammatory bowel diseases
(IBDs).7 However, to date, multiple random biopsies have to
be taken because only histopathology is currently able to
predict exact disease activity in IBD.8
As knowledge of the disease-speciﬁc ﬁndings in ulcerative
colitis is of crucial importance for the endoscopist, this video
highlights the various endoscopic ﬁndings in different disease
stages of ulcerative colitis. The technique of advanced dys-
plasia detection in ulcerative colitis will be highlighted in
another video of this library.
Key Learning Points/Tips and Tricks
• In the setting of severe inﬂammation, care should be taken
while advancing the endoscope and the indication of total
colonoscopy should be thought over, as perforation risk in
these patients is increased.
• The Mayo ulcerative endoscopic score of severity is a simple
classiﬁcation system to describe mucosal inﬂammation in
ulcerative colitis.
Mayo 0¼normal or inactive disease.
Mayo 1¼mild disease: erythema, decreased vascular pat-
tern, mild friability.
Mayo 2 ¼ moderate disease: frank friability, marked ery-
thema, absent vascular pattern, erosions.
Mayo 3¼severe disease: mucopus, spontaneous bleeding,
ulceration.
• Surveillance colonoscopy should be performed in inactive
disease stages.
• Advanced endoscopic imaging techniques, such as narrow
band imaging (NBI), Fuji Intelligent Color Enhancement
(FICE), or i-scan, can increase the prediction of disease





00:04 While Crohn’s disease is often characterized by a
discontinuous inﬂammation with longitudinal
ulcers, ulcerative colitis represents mostly as a
continuous inﬂammation starting in the rectum.
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This patient presents with severe bloody diarrhea.
Endoscopy reveals continuous mucosal
inﬂammation, starting in the rectum and mucopus,
ulcerations, and spontaneous bleeding
representative of a Mayo ulcerative colitis score
of 3. Histological analysis conﬁrmed diagnosis of
ulcerative colitis and the patient was put on
immunomodulating therapy, which resulted in a
rapid improvement of symptoms.
00:45 This case demonstrated a Mayo ulcerative
endoscopic score of 2. In comparison to Crohn’s
disease, ulcers in ulcerative colitis are more
superﬁcial and conﬂuent. Moreover, one can
visualize some frank friability, erythema, and
absent vascular pattern. Surveillance in the area of
acute inﬂammation is often unsatisfactory and
should be repeated after an adequate
immunosuppressive therapy.
01:15 Here, we perform colonoscopy in a patient suffering
from ulcerative colitis with mild disease activity
representing a Mayo ulcerative endoscopic score of
1. Mucosal changes include slight mucosal
erythema, decreased vascular pattern, and mild
friability. Superﬁcial and small erosions may also
occur.
Standard high-deﬁnition white light endoscopy
is only insensitive in the prediction of disease
activity and extent in patients with mild or
even inactive IBD. Nevertheless, recent data
indicate that the accuracy of endoscopy could be
signiﬁcantly improved by using advanced
endoscopic imaging modalities like NBI, FICE or
i-scan.
01:50 This case shows endoscopic ﬁndings in a patient with
inactive ulcerative colitis, representing a Mayo
ulcerative colitis score of 0. By using digital
chromoendoscopy, one can clearly visualize
mucosal scars that appear whitish.
02:09 Surveillance endoscopy is of crucial importance in
ulcerative colitis, as patients are at an increased
risk of development of colitis-associated cancer.
Chromoendoscopy, like in this case after
application of 0.1% methylene blue, may facilitate
detection of ﬂat lesions. The technique of advanced
dysplasia detection in ulcerative colitis will be
highlighted in another video of this work.
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